Information  X 
Enter a valid email address

Oxford Biomedica PLC Ord 1P (OXB)

Date Time Source Announcement
02 May 2019 2:53 pm
RNS
Long Term Incentive Plan Option Grant
01 May 2019 12:52 pm
RNS
REPLACEMENT: Total Voting Rights
30 Apr 2019 5:38 pm
RNS
Holdings in Company
  1:35 pm
RNS
Oxford Biomedica to present at the ASGCT
  1:15 pm
RNS
Axovant doses second cohort of AXO-Lenti-PD
25 Apr 2019 3:38 pm
RNS
Director Dealings / Market Share Purchase
23 Apr 2019 1:47 pm
RNS
Deferred Bonus Plan and LTIP Option Grants
  11:38 am
RNS
Director Dealings / Market Share Transactions
18 Apr 2019 5:33 pm
RNS
Exercise of warrants
  7:00 am
RNS
Annual Report and Accounts & AGM Notification
02 Apr 2019 7:15 am
EQS
Oxford BioMedica (OXB): Deal-making drives first annual profit
01 Apr 2019 11:40 am
RNS
Total Voting Rights
26 Mar 2019 12:57 pm
RNS
Director Dealings / Market Share Purchase
  8:25 am
RNS
Japanese approval of Kymriah? (tisagenlecleucel)
14 Mar 2019 7:00 am
RNS
Preliminary Results
12 Mar 2019 7:00 am
RNS
OXB announces R&D collaboration with Microsoft
11 Mar 2019 10:38 am
RNS
Axovant's update on Phase 2 trial of AXO-Lenti-PD
01 Mar 2019 9:30 am
RNS
Total Voting Rights
25 Feb 2019 12:23 pm
RNS
Director Dealings / Market Share Purchase
08 Feb 2019 7:00 am
RNS
Notice of Results
07 Feb 2019 11:49 am
RNS
Director/PDMR Shareholding
  9:22 am
RNS
Update on programmes outlicensed to Sanofi
06 Feb 2019 11:00 am
RNS
Director Dealings / Market Share Transactions
05 Feb 2019 10:22 am
RNS
Director Dealings / Market Share Purchase
01 Feb 2019 10:00 am
RNS
Total Voting Rights
24 Jan 2019 11:20 am
RNS
Director Dealings / Market Share Purchase
18 Jan 2019 10:51 am
RNS
Director Dealings / Market Share Purchase
03 Jan 2019 12:20 pm
RNS
Block listing Interim Review
02 Jan 2019 10:17 am
RNS
Total Voting Rights
21 Dec 2018 1:16 pm
RNS
Director Dealings / Market Share Purchase
06 Dec 2018 4:11 pm
RNS
Axovant FDA meeting feedback
03 Dec 2018 9:53 am
RNS
Total Voting Rights
  7:00 am
RNS
Longer term Kymriah efficacy and safety data
23 Nov 2018 10:41 am
RNS
Director Dealings
  7:00 am
RNS
Oxford Biomedica form digital framework initiative
09 Nov 2018 7:00 am
RNS
Block listing application
01 Nov 2018 2:41 pm
RNS
Total Voting Rights
25 Oct 2018 7:00 am
RNS
Axovant Doses First Patient with AXO-Lenti-PD
22 Oct 2018 4:39 pm
RNS
Director Dealings / Market Share Purchase
05 Oct 2018 7:00 am
RNS
Details of alliance with Orchard Therapeutics
01 Oct 2018 9:41 am
RNS
Total Voting Rights
24 Sep 2018 12:20 pm
RNS
Director/PDMR Shareholding
20 Sep 2018 10:55 am
EQS
Oxford BioMedica (OXB): Partnering strategy delivering profitability
13 Sep 2018 7:00 am
RNS
Oxford BioMedica Interim Results
  7:00 am
RNS
Oxford BioMedica further capacity expansion
03 Sep 2018 9:18 am
RNS
Total Voting Rights
28 Aug 2018 7:00 am
RNS
Kymriah? receives European Commission Approval
22 Aug 2018 11:58 am
RNS
Director/PDMR Shareholding
15 Aug 2018 7:00 am
RNS
RNS notice of results OXB
14 Aug 2018 7:15 am
EQS
Oxford BioMedica (OXB): Risk-sharing in cystic fibrosis gene-therapy
13 Aug 2018 10:55 am
RNS
Director/PDMR Shareholding
  10:48 am
RNS
Director/PDMR Shareholding
10 Aug 2018 11:39 am
RNS
PDMR Dealings / Market Share Sale
  11:36 am
RNS
Director Dealings / Market Share Sale and Purchase
08 Aug 2018 2:45 pm
RNS
Share Options and LTIPs Granted
06 Aug 2018 7:02 am
RNS
Partnership for Cystic Fibrosis Gene Therapy
01 Aug 2018 9:53 am
RNS
Total Voting Rights
23 Jul 2018 12:54 pm
RNS
Director Dealings / Market Share Purchase
02 Jul 2018 10:25 am
RNS
Directorate Change
  9:47 am
RNS
Total Voting Rights
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t